Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trials

4 recruiting

Gastric or Gastroesophageal Junction Adenocarcinoma Trials at a Glance

14 actively recruiting trials for gastric or gastroesophageal junction adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Shanghai, Shenyang, and Jinan. Lead sponsors running gastric or gastroesophageal junction adenocarcinoma studies include Antengene Biologics Limited, Beijing Biostar Pharmaceuticals Co., Ltd., and Akeso.

Browse gastric or gastroesophageal junction adenocarcinoma trials by phase

Treatments under study

About Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trials

Looking for clinical trials for Gastric or Gastroesophageal Junction Adenocarcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric or Gastroesophageal Junction Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric or Gastroesophageal Junction Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited132 enrolled30 locationsNCT07327229
Recruiting
Phase 3

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.600 enrolled2 locationsNCT07118527
Recruiting
Phase 3

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

ImmunotherapyAFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4+1 more
Hebei Medical University Fourth Hospital39 enrolled1 locationNCT07289997
Recruiting
Phase 2Phase 3

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.778 enrolled10 locationsNCT06841679
Recruiting
Phase 2

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Henlius Biotech60 enrolled1 locationNCT07115485
Recruiting
Phase 1Phase 2

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893
Recruiting
Phase 3

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.450 enrolled22 locationsNCT06238843
Recruiting
Phase 2

A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled1 locationNCT06423885
Recruiting
Phase 2

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University59 enrolled7 locationsNCT05585580
Recruiting
Phase 3

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.524 enrolled1 locationNCT06649292
Recruiting
Not Applicable

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

Pancreatic CancerAdenocarcinomaResectable Pancreatic Adenocarcinoma+3 more
University Hospital, Clermont-Ferrand100 enrolled1 locationNCT06649474
Recruiting
Phase 2

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital50 enrolled1 locationNCT06587425
Recruiting
Phase 2

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Akeso90 enrolled1 locationNCT05960955